VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 29, 2007) - EnWave Corporation (TSX VENTURE:ENW) (“EnWave” or “the Company”) is pleased to report that it has signed a Letter of Intent (“LOI”) to initiate a collaboration with Aridis Pharmaceuticals (“Aridis”) of San Jose, California, a leader in pharmaceutical formulation development. The collaboration will determine the feasibility of using EnWave’s bioREV technology to develop room temperature stable vaccines. The initial collaboration will process test quantities of several proprietary Aridis vaccine products to provide proof of concept data on the use of bioREV as a vaccine stabilization method. In addition to the initial collaboration, the LOI offers both parties an opportunity to expand the commercial relationship to include other vaccine products and joint intellectual property development with future product royalty incentives.
